Journal
JCI INSIGHT
Volume 7, Issue 19, Pages -Publisher
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/jci.insight.159863
Keywords
-
Categories
Funding
- Novavi Foundation
- Research Foundation, Mental Health Services, Capital Region of Denmark
- Capital Region of Denmark
- Ivan Nielsen Foundation
- A.P. Moeller Foundation
- Augustinus Foundation
- Woerzner Foundation
- Grosserer L.F. Foghts Foundation
- Hartmann Foundation
- Aase and Ejnar Danielsen Foundation
- P.A. Messerschmidt and Wife Foundation
- Lundbeck Foundation
Ask authors/readers for more resources
This study provides new knowledge on the effects of a glucagon-like peptide-1 (GLP-1) receptor agonist, exenatide, in patients with alcohol use disorder (AUD). Although exenatide did not significantly reduce the number of heavy drinking days compared to placebo, it attenuated fMRI alcohol cue reactivity and dopamine transporter availability in crucial brain areas for drug reward and addiction. In a subgroup of obese patients, exenatide significantly reduced heavy drinking days and total alcohol intake. Adverse events mainly consisted of gastrointestinal reactions.
BACKGROUND. Alcohol use disorder (AUD) is a chronic, relapsing brain disorder that accounts for 5% of deaths annually, and there is an urgent need to develop new targets for therapeutic intervention. The glucagon-like peptide-1 (GLP-1) receptor agonist exenatide reduces alcohol consumption in rodents and nonhuman primates, but its efficacy in patients with AUD is unknown.METHODS. In a randomized, double-blinded, placebo-controlled clinical trial, treatment-seeking AUD patients were assigned to receive exenatide (2 mg subcutaneously) or placebo once weekly for 26 weeks, in addition to standard cognitive-behavioral therapy. The primary outcome was reduction in number of heavy drinking days. A subgroup also completed functional MRI (fMRI) and single -photon emission CT (SPECT) brain scans.RESULTS. A total of 127 patients were enrolled. Our data revealed that although exenatide did not significantly reduce the number of heavy drinking days compared with placebo, it significantly attenuated fMRI alcohol cue reactivity in the ventral striatum and septal area, which are crucial brain areas for drug reward and addiction. In addition, dopamine transporter availability was lower in the exenatide group compared with the placebo group. Exploratory analyses revealed that exenatide significantly reduced heavy drinking days and total alcohol intake in a subgroup of obese patients (BMI > 30 kg/m2). Adverse events were mainly gastrointestinal.CONCLUSION. This randomized controlled trial on the effects of a GLP-1 receptor agonist in AUD patients provides new important knowledge on the effects of GLP-1 receptor agonists as a novel treatment target in addiction.TRIAL REGISTRATION. EudraCT: 2016-003343-11. ClinicalTrials.gov (NCT03232112).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available